Your question is Mitigating Allogeneic GVHD Risks. Take a moment with it on the right.
Talk me through your thinking if you like. When you're confident, submit your answer and I'll grade it like a real screen (7/10 or better passes).
How do you approach clearing host-versus-graft or graft-versus-host disease risks in an allogeneic platform like Allogene Therapeutics' off-the-shelf CAR T therapies?